查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1786464

全球药物传输设备市场

Drug and Gene Delivery Devices
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 278 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球药物传输设备市场规模将达到 22 亿美元

全球给药装置市场规模预计在2024年为14亿美元，到2030年将达到22亿美元，在2024-2030年的分析期间内，复合年增长率为7.5%。口服给药是本报告分析的细分市场之一，预计其复合年增长率为7.0%，到分析期结束时将达到5.103亿美元。吸入给药细分市场在分析期间的复合年增长率预计为8.9%。

美国市场规模估计为 3.861 亿美元，中国市场预计复合年增长率为 11.6%

美国药物输送装置市场规模预计2024年达到3.861亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到4.59亿美元，在2024-2030年的分析期间内，复合年增长率为11.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为3.8%和7.2%。在欧洲，预计德国市场的复合年增长率为5.0%。

全球药物输送设备市场－主要趋势与驱动因素摘要

药物输送装置方面有哪些突破性创新？

在生物技术、奈米医学和先进材料科学领域尖端创新的推动下，药物传输装置市场正在迅速转型。这些装置不再只是治疗的载体，而是日益复杂的平台，能够增强药物和遗传物质的特异性、稳定性和生物有效性。 CRISPR-Cas9 和RNA干扰(RNAi) 等技术的蓬勃发展，要求输送系统能够精准标靶化受影响的细胞，同时最大限度地减少脱靶效应。脂质奈米颗粒、病毒载体和电穿孔技术等新型传递机制应运而生，为这些精准治疗提供支援。此外，基于聚合物的传输载体和微针阵列也正在积极开发，以克服生物屏障并改善全身吸收，特别适用于需要进入细胞内的基因疗法。这些进展使得先前因输送限製而无法实现的疗法成为可能。

为什么个人化医疗会推动对新交付平台的需求？

个人化医疗和精准医疗的转变正在重新定义治疗递送需求，使得客製化药物递送装置的开发至关重要。根据个体基因特征客製化治疗方案需要能够适应各种分子量、溶解度和组织标靶的递送系统。随着基因组定序速度的加速和便利性提升，市场对患者个人化治疗的需求日益增长，尤其是在肿瘤学、罕见疾病和慢性病领域。这推动了对灵活、模组化且可快速配置的递送系统的需求。此外，将小分子与基因有效载荷结合的联合治疗的兴起，使得双重多模态递送能力成为必要。监管机构也不断改进相关框架，以应对个人化治疗的复杂性，从而加速下一代递送装置的核准和上市。

非侵入性和有针对性的交付方法将在市场发展中发挥什么作用？

病患偏好和医疗服务提供者优先顺序的不断变化，促使人们对非侵入性和特异性给药技术投入巨额资金。口服、鼻腔、肺部和经皮给药系统由于患者依从性和给药便捷性，比注射剂更受欢迎。尤其是吸入式基因治疗领域发展势头强劲，为囊肿纤维化和肺动脉高压等呼吸系统疾病提供了切实可行的替代方案。配备感测器、微处理器和连接功能的智慧给药设备也促进了这一转变，能够即时监控治疗的实施和疗效。这些设备正成为数位健康生态系统的重要组成部分，尤其是在居家照护环境中。此外，透过抗体药物复合体(ADC)、适体系统和磁场引导奈米粒子实现的特异性靶向作用，可以降低全身毒性并增强治疗效果，为更安全、更有效的治疗铺平道路。

药物输送装置市场的成长受到多种因素的推动…

奈米和微米工程技术的快速进步正在彻底改变递送平台的设计和性能，实现前所未有的控释和靶向递送。慢性病和遗传疾病的增多，加上基因治疗和核酸药物临床试验的增加，正在推动市场对客製化递送系统的需求。从最终用途的角度来看，製药公司正在大力投资下一代递送系统，以区分生物製药组合併透过新配方延长专利期。学术研究机构和委外研发机构(CRO) 也透过合作开发专案为扩大产品线做出贡献。在消费者方面，人们越来越偏好微创或自我管理的治疗方法，尤其是在老年人口和儿科护理中。同时，医疗保健提供者正在寻求与数据生态系统整合的递送解决方案，以便监测患者和优化治疗。这些趋势结合，正在全球创造一个强劲而充满活力的市场格局。

部分

给药途径（口服、吸入、经皮、注射、眼部、鼻部、局部）；载体（病毒、非病毒）

受访公司范例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company（BD）
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Kite Pharma, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Oxford BioMedica plc
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP30606

Global Drug and Gene Delivery Devices Market to Reach US$2.2 Billion by 2030

The global market for Drug and Gene Delivery Devices estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$510.3 Million by the end of the analysis period. Growth in the Inhalation segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.1 Million While China is Forecast to Grow at 11.6% CAGR

The Drug and Gene Delivery Devices market in the U.S. is estimated at US$386.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$459.0 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Drug and Gene Delivery Devices Market - Key Trends & Drivers Summarized

How Are Breakthrough Innovations Reshaping Drug and Gene Delivery Devices?

The drug and gene delivery devices market has undergone rapid transformation, driven by cutting-edge innovations in biotechnology, nanomedicine, and advanced material sciences. These devices are no longer just conduits for therapeutic agents but are becoming increasingly sophisticated platforms that enhance specificity, stability, and bioavailability of drugs and genetic material. Techniques like CRISPR-Cas9 and RNA interference (RNAi) have surged in prominence, requiring delivery systems that can precisely target affected cells while minimizing off-target effects. Novel delivery mechanisms such as lipid nanoparticles, viral vectors, and electroporation technologies have emerged to support these precision therapies. Additionally, polymer-based delivery vehicles and microneedle arrays are being actively developed to overcome biological barriers and improve systemic absorption, especially for gene therapies requiring intracellular access. These developments are enabling therapies that were previously not viable due to delivery limitations.

Why Is Personalized Medicine Fueling the Demand for Novel Delivery Platforms?

The transition toward personalized and precision medicine has redefined therapeutic delivery requirements, making the development of customized drug and gene delivery devices essential. Tailoring treatments based on individual genetic profiles demands delivery systems that can adapt to varying molecular weights, solubility characteristics, and tissue targets. As genomic sequencing becomes faster and more accessible, the market is experiencing increased demand for patient-specific therapies, particularly in oncology, rare diseases, and chronic conditions. This has led to a growing need for flexible and modular delivery systems that can be rapidly configured. Furthermore, the rise of combination therapies-blending small molecules with genetic payloads-necessitates dual or multi-modal delivery capabilities. Regulatory agencies are also evolving their frameworks to accommodate the complex nature of personalized therapeutics, which is accelerating approvals and market entry of next-generation delivery devices.

What Role Do Non-Invasive and Targeted Delivery Methods Play in Market Evolution?

Shifting patient preferences and healthcare provider priorities have spurred significant investment in non-invasive and site-specific delivery technologies. Oral, nasal, pulmonary, and transdermal routes are gaining popularity over injectable formats due to better patient compliance and ease of administration. In particular, the inhalable gene therapy segment is gaining momentum, offering a practical alternative for respiratory diseases such as cystic fibrosis and pulmonary hypertension. Smart delivery devices equipped with sensors, microprocessors, and connectivity features are also contributing to this shift, enabling real-time monitoring of therapeutic administration and outcomes. These devices are becoming integral to digital health ecosystems, especially in home-care settings. Moreover, site-specific targeting-achieved through antibody-drug conjugates (ADCs), aptamer systems, and magnetic field-guided nanoparticles-is reducing systemic toxicity and enhancing therapeutic efficacy, paving the way for safer, more efficient treatments.

The Growth in the Drug and Gene Delivery Devices Market Is Driven by Several Factors…

Rapid technological advancements in nano- and micro-scale engineering have revolutionized the design and performance of delivery platforms, enabling controlled release and targeted delivery like never before. The rise in chronic and genetic diseases, alongside increasing clinical trials for gene therapies and nucleic acid-based drugs, is propelling market demand for compatible delivery systems. From an end-use perspective, pharmaceutical companies are investing heavily in next-gen delivery systems to differentiate their biologic portfolios and extend patent life through novel formulations. Academic research institutions and contract research organizations (CROs) are also contributing to pipeline expansion through collaborative development programs. On the consumer side, there is a growing preference for minimally invasive or self-administrable treatment modalities, especially in the aging population and pediatric groups. In parallel, healthcare providers are seeking delivery solutions that integrate with data ecosystems for patient monitoring and treatment optimization. Together, these trends are forging a robust and dynamic market landscape for drug and gene delivery devices globally.

SCOPE OF STUDY:

The report analyzes the Drug and Gene Delivery Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical); Vector (Viral, Non-viral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company (BD)
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Kite Pharma, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Oxford BioMedica plc
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Drug and Gene Delivery Devices - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Chronic and Genetic Disorders Accelerates Demand for Advanced Drug and Gene Delivery Devices
    • Breakthroughs in mRNA Technology Strengthen the Business Case for Next-Generation Delivery Platforms
    • Growing Pipeline of Biologics and Cell & Gene Therapies Expands Addressable Market Opportunity for Novel Delivery Systems
    • Emergence of Personalized Medicine Spurs Innovation in Targeted and Localized Delivery Technologies
    • Favorable Regulatory Pathways and Fast-Track Approvals Propel Growth in Gene Therapy Delivery Solutions
    • Advancements in Nanocarriers and Lipid-Based Delivery Systems Drive Adoption in Precision Medicine
    • Increased Focus on Blood-Brain Barrier Penetration Throws the Spotlight on Intranasal and Intrathecal Delivery Methods
    • Rising Investment in Non-Viral Vectors Enhances Market Potential for Safer and Scalable Gene Delivery Approaches
    • Minimally Invasive Delivery Techniques Generate Demand for Needle-Free and Implantable Drug Delivery Devices
    • Shift Toward At-Home Treatment Models Sustains Growth of Wearable and Self-Administered Drug Delivery Systems
    • Strategic Collaborations Between Pharma and MedTech Firms Propel Innovation in Hybrid Drug-Device Products
    • Challenges in Payload Stability and Targeted Delivery Create Opportunities for Formulation-Device Integration
    • Growing Global Access to Advanced Therapies Drives Expansion of Drug and Gene Delivery Infrastructure in Emerging Markets
    • Evolving Regulatory Standards for Combination Products Create Both Hurdles and Opportunities in Product Commercialization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Drug and Gene Delivery Devices Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Drug and Gene Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ocular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ocular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ocular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Nasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Non-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Non-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Non-viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • CHINA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Drug and Gene Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • INDIA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Drug and Gene Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Drug and Gene Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • AFRICA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030

IV. COMPETITION